Pharm Tech Agenda 2022.01.07

Agenda

• Update on work items
  • Medication Management
  • Supply
  • Vaccination
  • Others (Adverse Event, Medication Record/Lists, Catalogs)

• Update on collaboration with other projects and SDOs
  • OpenHIE (Vaccination)
  • HL7
  • ISO
  • UNICOM
  • National initiaties
    • HL7 Belgium

Welcome

• Participants
  • Marc Robberecht
  • Anne van Berkel Meier
  • Quentin Ligier
  • Hernany Silva Costa Melo
  • João Almeida
  • Michael Tan
  • José Costa Teixeira

• Review and Approve Agenda
  • Agenda approved

Work items

• Supply (Project lead: Jose)
  • GS1 colleagues (Anne and Sylvia) are working on the use cases
  • Vaccination requires supply more strongly (there are discussions that would benefit from a standard Supply Chain interoperability --> Opportunity for IHE)
    • Marc and José are requested to look into the transactions and start writing up the content (even if not final) just to start checking how far we are with the technical details. Due 2022-01-28 (for the next Supply call).

• MM FHIR profiles
  • Current Status:
    • We had a deep dive in the last call, where we started dsicussing the main actors for the delivery/dispense process, and we started the discussion about whether "Pharmacy Validation" / (aka Pharmaceutical Advice) would be a separate transaction OR an update on the order itself
    • João is due to add a diagram to show how the actors can interact with each other - e.g. how the validation would be implemented.

Current option: having separate Pharmaceutical Advice as a separate thing (and Planning as yet another separate)

Marc brings one reason for keeping actors separately. Pharmacy validation can be part of the dispense process - e.g. in France. Hernany reminds that we discussed the action could be called "Order Review"

José proposes a requirement: whatever is the choice (single actor or separate actors), we should be able to "cascade" the actors/transactions (e.g. order entry sends an order to another order entry to update, which sends another order to do some checking). The reason for this requirement is that the sequence of the order entry (i.e. how many times does it get reviewed / validated / approved / signed) is not fixed upfront, so by having a cascaded model we can support this flexibility.

Use Cases are being listed in github issue #6: https://github.com/IHE/pharm-mm/issues/6

Marc mentions the ongoing work on HL7 France ImplementationGuide. This is expected to be released by end of January 2022 https://simplifier.net/guide/fr-Medication/Priseenchargemdicamenteusedupatient

• Vaccination (Project lead Juergen)

Vaccination topic slowed down recently, due to lack of formal engagement/commitment. Basically we are back at working on a volunteer / collaborative effort. Still, some good outcomes worth pursuing:

• • OpenHIE is interested in aligning architecture discussions on Vaccination (at least vaccination event)
  • Scope will be refined as we start working on the topic.
  • Several countries already have a worrking / tentative solution for vaccination (event) registration, e.g. Switzerland (CDA & FHIR), Germany (FHIR - one of their MIOs), Austria (CDA)
  • In Belgium there is a proprietary system (Vaccinnet) and standard (KMEHR) There is plan for migration but there are efforts to continue defining a Belgian standard for vaccination event.

• Medication record (Project lead Jose)
• José mentions the effort of separating MedicationTreatmentLine (e.g. physician 1 prescribes Paracetamol EG 100 mg ; physician 2 prescribes Dafalgan 500 mg) and MedicationViewLine (for example a patient still has 2 medications to take, but a physician wants to have a list grouped by active substance - 1 line for Paracetamol)
• Michael mentions the Dutch approach - between the Therapy/Clinical part of the treatment, and the logistics part of the treatment. - we should align the perspectives by exposing the models. Michael volunteers José to exchange the Belgian model and will procure the Dutch approach (or people that are willing to share the approach) for a first impression.
• Hernany also mentions another dimension - the generic vs brand definition of the product
  • Also prescribed medication vs medication that was not prescribed.
• Anne also confirms that the relation between products (generic, brand..) is the knowlege that is in the system (or in the heads of people)